Small trial demonstrates the effectiveness of Chrono Therapeutics’ smoking cessation tech
When compared to subjects treated with placebo, test subjects had a statistically significant and clinically meaningful reduction in cravings.
Chrono Therapeutics receives second Fast Track SBIR grant from the NCI
The award of up to $2.3M will support final product development of the digital portion of Chrono's patient-individualized smoking cessation therapy.
Rock Health backs Chrono Therapeutics’ smoking cessation wearable
The company makes the SmartStop device which is worn on the arm or body, and used as a drug (nicotine) delivery tool that works with a companion mobile app.
Chrono Therapeutics secures $32 million to further develop its smoking cessation technology
The Series A round was raised from a number of investors, including Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures.